A common antibiotic used to treat liver disease could give rise to an “almost untreatable” superbug, scientists warned in a new study. The antibiotic, rifaximin, has enabled the global emergence of ...
Rifaximin prophylaxis was no better than placebo at preventing deaths and other negative outcomes from spontaneous bacterial peritonitis (SBP) in patients with severe cirrhosis, according to interim ...
Rifaximin improves the gut microenvironment by reducing the abundance of harmful bacteria while increasing probiotic bacteria. It inhibits the translocation of bacteria from the mouth to the intestine ...
Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...
A new study has found that an antibiotic for liver disease patients could expose them to greater risk of a dangerous superbug. The international team of researchers found that an antibiotic commonly ...
The associated underlying disease is used to classify hepatic encephalopathy: type A is related to acute liver injury, type B is related to portosystemic shunting, and type C is related to cirrhosis.
Rifaximin improves the gut microenvironment by reducing the abundance of harmful bacteria while increasing probiotic bacteria. It inhibits the translocation of bacteria from the mouth to the intestine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results